Cancer Treatment News and Research

RSS

Antisense Therapeutics trial of ATL1101 in prostate cancer shows promise

Antisense Therapeutics Ltd. (ASX: ANP) has reported further positive results from its collaborative preclinical research studies on the therapeutic potential of ATL1101 in prostate cancer. In experimental models, ATL1101 treatment significantly enhanced the tumor-suppressive effect of the cancer drug Paclitaxel. Paclitaxel is one of a class of drugs known as taxanes.

18 Jun 2009

Novel light-sensitive compounds show promise for photodynamic cancer therapy

Chemists at the University of California, Santa Cruz, have developed novel compounds that show promise for photodynamic cancer therapy, which uses light-activated drugs to kill tumor cells.

17 Jun 2009

Taxol-carrying nanoparticles

Nanoparticles specially engineered by University of Central Florida Assistant Professor J. Manuel Perez and his colleagues could someday target and destroy tumors, sparing patients from toxic, whole-body chemotherapies.

17 Jun 2009

New form of radiotherapy could revolutionize treatment for recurrent prostate cancer

A new study shows that an alpha-particle emitting radiopeptide - radioactive material bound to a synthetic peptide, a component of protein - is effective for treating prostate cancer in mice, according to researchers at SNM's 56th Annual Meeting in Toronto.

15 Jun 2009

Research leads to advanced trials of new cancer treatment

Prof. Hochberg was successful in isolating the H19 gene in humans and determining that it is significantly expressed in over 33 different forms of cancer, including superficial bladder carcinoma and pancreatic, ovarian and metastatic liver cancer, while laying dormant and non-expressed in non-cancerous cells.

15 Jun 2009

Prevalence and predictors of antioxidant supplement use during breast cancer treatment

A new study finds that many women with breast cancer take antioxidant supplements while undergoing cancer treatment, even though the consequences of doing so are unknown.

9 Jun 2009

Cisplatin doubles lung cancer survival time in mice

A lung cancer treatment that inhibits nicotine receptors was shown to double survival time in mice, according to Italian researchers.

9 Jun 2009

Prophylactic cranial irradiation prevents early lung cancer metastases to the brain

A national Radiation Therapy Oncology Group (RTOG) study led by a Medical College of Wisconsin Cancer Center physician at Froedtert Hospital in Milwaukee has found that a course of radiation therapy to the brain after treatment for locally advanced non-small cell lung cancer reduced the risk of metastases to the brain within the first year after treatment. The study was presented at the American Society of Clinical Oncology annual meeting in Orlando, June 1.

3 Jun 2009

Bringing life back into the bedroom for cancer survivors

For the more than 6 million female cancer survivors living in the U.S. today, the celebration of continued life and love can be interrupted by cancer treatment's side effects, including in the bedroom. Experts at The University of Texas M. D. Anderson Cancer Center offer survivors advice on how to get their relationships back on track.

2 Jun 2009

Chemotherapy combination outcomes differ for aged, younger colon cancer patients

The combination of chemotherapies 5FU and oxaliplatin compared to 5FU alone after surgery for colon cancer decreases colon cancer recurrence and promotes longer survival for patients under 70 -- but not for those who are older, according to Mayo Clinic and Dana-Farber Cancer Institute scientists who will present their findings at the American Society of Clinical Oncology's (ASCO) annual meeting in Orlando, Fla.

1 Jun 2009

Popular antidepressants taken with tamoxifen can increase the risk of breast cancer recurrence

A new study found that taking tamoxifen with certain antidepressants more than doubled the risk of breast cancer recurrence in women taking both medications. The antidepressants inhibit an enzyme, CYP2D6, which helps tamoxifen work effectively.

1 Jun 2009

African-American women breast cancer sufferers often refuse chemotherapy and radiation therapy

A new study finds that nearly one in four African American women with late stage breast cancer refused chemotherapy and radiation therapy, potentially life saving therapies.

22 May 2009

Research suggests role of low vitamin D in cancer

In studying the preventive effects of vitamin D, researchers at the Moores Cancer Center at the University of California, San Diego, have proposed a new model of cancer development that hinges on a loss of cancer cells' ability to stick together. The model, dubbed DINOMIT, differs substantially from the current model of cancer development, which suggests genetic mutations as the earliest driving forces behind cancer.

22 May 2009

Genetic signature predicts clinical outcomes in certain types of breast cancer

Vanderbilt-Ingram Cancer Center researchers have uncovered a gene signature that may help predict clinical outcomes in certain types of breast cancer.

19 May 2009

Many low-income women breast cancer patients skipping hormonal therapy, lowering their survival rates

Many low-income women are failing to take the hormonal therapy prescribed as part of their breast cancer treatment, possibly lowering their survival rates, according to a study led by a researcher in the Duke Comprehensive Cancer Center.

18 May 2009

Pregabalin shows potential as treatment for hot flashes

A pill used for nerve pain offers women relief from hot flashes, Mayo Clinic researchers report at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO).

17 May 2009

Low oxygen levels in prostate tumors can predict recurrence

Fox Chase Cancer Center researchers have discovered that low-oxygen regions in prostate tumors can be used to predict a rise in prostate-specific antigen (PSA) levels, a marker of tumor recurrence in prostate cancer.

17 May 2009

New system to deliver siRNA into primary cells

In technology that promises to one day allow drug delivery to be tailored to an individual patient and a particular cancer tumor, researchers at the University of California, San Diego School of Medicine, have developed an efficient system for delivering siRNA into primary cells.

17 May 2009

Cancer rates among U.S. elderly, minorities set to explode

Over the next 20 years, the number of new cancer cases diagnosed annually in the United States will increase by 45 percent, from 1.6 million in 2010 to 2.3 million in 2030, with a dramatic spike in incidence predicted in the elderly and minority populations, according to research from The University of Texas M. D. Anderson Cancer Center.

29 Apr 2009